Cubist Inks Deal To Buy Trius, Optimer For Up To $1.6B

Law360, Los Angeles (July 30, 2013, 7:44 PM EDT) -- Cubist Pharmaceuticals Inc. said Tuesday it would acquire all shares of Trius Therapeutics Inc. and Optimer Pharmaceuticals Inc. in two transactions worth up to $1.62 billion, boosting the company’s leadership in the acute care hospital market.

Cubist said it would pay up to $818 million for Trius, a biopharmaceutical company that brings its highly complementary, late-stage antibiotic candidate tedizolid phosphate, and up to $801 million for Jersey City, N.J.-based Optimer, a global biopharmaceutical company currently focused on commercializing its antibiotic product DIFICID, or fidaxomicin, in the...
To view the full article, register now.